Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA

Key Takeaways:

• Investors filed a class action lawsuit against Humacyte, Inc. alleging securities fraud.
• The lawsuit claims Humacyte concealed manufacturing deficiencies at its Durham facility.
• Alleged deficiencies included non-compliance with good manufacturing practices and issues with quality assurance and microbial testing.
• The FDA’s review of Humacyte’s biologics license application was delayed as a result.
• Investors have until January 17, 2025, to request appointment as lead plaintiff.

Humacyte Faces Class Action Lawsuit

Investors Allege Securities Fraud Over Manufacturing Deficiencies

Investors in Humacyte, Inc. (NASDAQ: HUMA) have filed a class action lawsuit alleging that the biotechnology company engaged in securities fraud by concealing critical information about manufacturing deficiencies at its Durham, North Carolina, facility. The lawsuit was announced by law firm Levi & Korsinsky, LLP, on January 10, 2025.

Allegations of Concealed Manufacturing Issues

The complaint asserts that between May 10, 2024, and October 17, 2024, Humacyte failed to disclose that its Durham facility was not in compliance with good manufacturing practices (GMP), specifically regarding quality assurance and microbial testing procedures. These alleged deficiencies, according to the lawsuit, posed a substantial risk to the approval of the company’s acellular tissue-engineered vessel for vascular trauma by the U.S. Food and Drug Administration (FDA).

Delays in FDA Review

As a result of the purported manufacturing issues, the FDA’s review of Humacyte’s biologics license application was delayed while the company worked to remediate the deficiencies. The lawsuit claims that Humacyte’s positive statements about its business, operations, and prospects during this period were materially misleading or lacked a reasonable basis due to the undisclosed risks.

Investor Losses and Legal Action

The class action seeks to recover losses on behalf of investors who purchased Humacyte securities during the specified period and were adversely affected by the alleged securities fraud. Investors have until January 17, 2025, to request that the court appoint them as lead plaintiff in the case. Participation in the lawsuit does not require serving as lead plaintiff, and there are no out-of-pocket costs or fees to join the action.

Law Firm’s Track Record

Levi & Korsinsky, LLP, the firm representing the plaintiffs, has a history of securing significant recoveries for shareholders. Over the past 20 years, the firm has obtained hundreds of millions of dollars for aggrieved investors and has built a reputation for handling high-stakes securities litigation. With a team of over 70 employees, the firm emphasizes its extensive expertise in representing investors in complex legal matters.

Next Steps for Affected Shareholders

Investors who suffered losses during the relevant time frame are encouraged to contact Levi & Korsinsky to discuss their legal rights and options. Joseph E. Levi, Esq., can be reached via email at